A Phase 1/2, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX112) in Subjects With Relapsed or Refractory B Cell Malignancies

  • Si Lun Tam, Con (Primary Chief Investigator (PCI))
  • Cheah, Chan (Chief Investigator (CI))

Project: Research

Project Details

StatusActive
Effective start/end date4/08/23 → 4/08/25

Keywords

  • clinical trial
  • B Cell Malignancies
  • CRISPR-Cas9
  • CD19